Marie-Paule Lachambre

Marie-Paule Lachambre

Auto-generated profile, based on publicly available information

Marie-Paule Lachambre

Laboratoire de Médecine Moléculaire, Department of Neurosurgery, CHUM and UQAM, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in Vascular Pharmacology
Verified
Journal Article
Closed access
SLSylvie Lamy
Sylvie Lamy
MLMarie-Paule Lachambre
Marie-Paule Lachambre
SLSimon Lord-Dufour
Simon Lord-Dufour
RBRichard Béliveau
Richard Béliveau

1 January 2002 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
BABorhane Annabi
Borhane Annabi
MLMarie-Paule Lachambre
Marie-Paule Lachambre
NBNathalie Bousquet-Gagnon
Nathalie Bousquet-Gagnon
MPMartine Pagé
Martine Pagé
DGDenis Gingras
Denis Gingras
RBRichard Béliveau
Richard Béliveau

1 November 2009 in Pharmacological Research
Verified
Journal Article
Closed access
BABorhane Annabi
Borhane Annabi
MLMarie-Paule Lachambre
Marie-Paule Lachambre
KPKarine Plouffe
Karine Plouffe
RMRobert Moumdjian
Robert Moumdjian
RBRichard Béliveau
Richard Béliveau

15 October 2001 in FEBS Letters
Verified
Journal Article
Closed access
DGDenis Gingras
Denis Gingras
NBNathalie Bousquet-Gagnon
Nathalie Bousquet-Gagnon
SLStéphanie Langlois
Stéphanie Langlois
MLMarie-Paule Lachambre
Marie-Paule Lachambre
BABorhane Annabi
Borhane Annabi
RBRichard Béliveau
Richard Béliveau

1 February 2001 in Biochemical Journal
Verified
Journal Article
Closed access
BABorhane Annabi
Borhane Annabi
MLMarie-Paule Lachambre
Marie-Paule Lachambre
NBNathalie Bousquet-Gagnon
Nathalie Bousquet-Gagnon
MPMartine Pagé
Martine Pagé
DGDenis Gingras
Denis Gingras
RBRichard Béliveau
Richard Béliveau

9 March 2009 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
BABorhane Annabi
Borhane Annabi
CLCarl Laflamme
Carl Laflamme
ASAsmaa Sina
Asmaa Sina
MLMarie-Paule Lachambre
Marie-Paule Lachambre
RBRichard Béliveau
Richard Béliveau
Background: The CD133(+) stem cell population in recurrent gliomas is associated with clinical features such as therapy resistance, blood-brain barrier disruption and, hence, tumor infiltration. Screening of a large panel of glioma samples increasing histological grade demonstrated frequencies of CD133(+) cells which correlated with high expression of cyclooxygenase (COX)-2 and of membrane type-1 matrix metalloproteinase (MT1-MMP). Methods: We used qRT-PCR and immunoblotting to examine the molecular interplay between MT1-MMP and COX-2 gene and protein expression in parental, CD133(+), and neurospheres U87 glioma cell cultures. Results: We found that CD133, COX-2 and MT1-MMP expression were enhanced when glioma cells were cultured in neurosphere conditions. A CD133(+)-enriched U87 glioma cell population, isolated from parental U87 cells with magnetic cell sorting technology, also grew as neurospheres and showed enhanced COX-2 expression. MT1-MMP gene silencing antagonized COX-2 expression in neurospheres, while overexpression of recombinant MT1-MMP directly triggered COX-2 expression in U87 cells independent from MT1-MMP's catalytic function. COX-2 induction by MT1-MMP was also validated in wild-type and in NF-κB p65-/- mutant mouse embryonic fibroblasts, but was abrogated in NF-κB1 (p50-/-) mutant cells. Conclusion: We provide evidence for enhanced COX-2 expression in CD133(+) glioma cells, and direct cell-based evidence of NF-κB-mediated COX-2 regulation by MT1-MMP. The biological significance of such checkpoint control may account for COX-2-dependent mechanisms of inflammatory balance responsible of therapy resistance phenotype of cancer stem cells.